Regulatory tracker: FDA accepts Roche's application for Lunsumio-Polivy combo
β’ The FDA has accepted Roche's application to use the combination of Lunsumio and Polivy for patient treatment. β’ This regulatory milestone is part of Roche's effort to expand the indications and clinical utility of these existing in-market products. β’ The development matters as it potentially provides a new therapeutic option for patients requiring this specific drug combination.
fiercepharma.com